Biosergen AB (publ)

DB:8N10 Stock Report

Market Cap: €1.4m

Biosergen Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Tine Olesen

Chief executive officer

SEK 1.9m

Total compensation

CEO salary percentage100.00%
CEO tenure2.4yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure2.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tine Olesen's remuneration changed compared to Biosergen's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025SEK 2mSEK 2m

-SEK 38m

Sep 30 2025n/an/a

-SEK 31m

Jun 30 2025n/an/a

-SEK 23m

Mar 31 2025n/an/a

-SEK 17m

Dec 31 2024SEK 2mSEK 2m

-SEK 19m

Compensation vs Market: Tine's total compensation ($USD191.92K) is below average for companies of similar size in the German market ($USD464.74K).

Compensation vs Earnings: Tine's compensation has increased whilst the company is unprofitable.

CEO

Tine Olesen

2.4yrs
Tenure
SEK 1,872,000
Compensation

Ms. Tine Kold Olesen, Ph D., serves as Chief Executive Officer of Biosergen AB since February 1, 2024. She served as Chief Operation Officer of Biosergen since March 2022 until February 1, 2024 and served...

Board Members

NamePositionTenureCompensationOwnership
Sergey Zotchev
Chief Scientific Officer and Member of Scientific Advisory Panelno datano datano data
Marco Taglietti
Director1.1yrsno datano data
Anna Ljung
Director2.1yrsSEK 400.00kno data
Mattias Klintemar
Chairman5.5yrsSEK 200.00kno data
Marianne Kock
Independent Deputy Chairperson5.5yrsSEK 300.00kno data
Robert Molander
Independent Board Member2.1yrsSEK 200.00kno data
2.1yrs
Average Tenure
61yo
Average Age

Experienced Board: 8N10's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 00:35
End of Day Share Price 2026/07/23 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biosergen AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Herman KuntscherCarlsquare AB